Open access · OA
via OpenAlex
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton, Paul Silcocks, Trevor F. Cox, Juan W. Valle, Jonathan Wadsley, David Propper, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom Roques, David Cunningham, Stephen Falk, Nick Wadd, Mark Harrison, Pippa Corrie
The Lancet Oncology · 2014 · ▲ 375 citations
Abstract
This phase 3 trial from The Lancet Oncology in 2014 evaluates the efficacy of gemcitabine and capecitabine with or without the vaccine GV1001.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/s1470-2045(14)70236-0
- Canonical
- link ↗
- Fetched
- 2026-08-31 MST
Cite this
APA
Middleton, G., Silcocks, P., Cox, T.F., Valle, J.W., Wadsley, J., Propper, D., Coxon, F.Y., Ross, P.J., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Robinson, A., McAdam, K., Eatock, M., & EVANS, J. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <em>The Lancet Oncology</em>. https://doi.org/10.1016/s1470-2045(14)70236-0
Vancouver
Middleton G, Silcocks P, Cox TF, Valle JW, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology. 2014. doi:10.1016/s1470-2045(14)70236-0.
BibTeX
@article{gary2014Gemcit,
title = {Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial},
author = {Gary Middleton and Paul Silcocks and Trevor F. Cox and Juan W. Valle and Jonathan Wadsley and David Propper and Fareeda Y. Coxon and Paul J. Ross and Srinivasan Madhusudan and Tom Roques and David Cunningham and Stephen Falk and Nick Wadd and Mark Harrison and Pippa Corrie and Timothy Iveson and Angus Robinson and Karen McAdam and Martin Eatock and JEFF EVANS and Caroline Archer and Tamas Hickish and Angel Garcia-Alonso and M. Nicolson and William P. Steward},
journal = {The Lancet Oncology},
year = {2014},
doi = {10.1016/s1470-2045(14)70236-0},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell 1997
Open access · OA
Life and Cancer Without Telomerase
National Cancer Institute, Naples 2011
Open access · US-GOV
Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.
Acta Neuropathologica 2019
Open access · OA
Neurotoxicity of pesticides
Hoffmann-La Roche 2010
Open access · US-GOV
Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES
University College, London 2012
Open access · US-GOV
Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy
Hellenic Oncology Research Group 2006
Open access · US-GOV